Clinical trial
Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
NCT03849131 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
- Lead sponsor
- University Hospital, Strasbourg, France
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- November 29, 2019
- Completion date
- June 30, 2025
- Enrollment
- 905 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
opportunistic autoimmune diseases